Class action accuses a 'GLP-1 patch' seller of selling a product with no GLP-1 in it

A newly filed class action alleges that Ledisa LLC sold adhesive "GLP-1 Patches" that contain no GLP-1 hormone and no GLP-1 receptor agonist of any kind, despite marketing that promised "sustained appetite control" and claimed the patches could "trigger GLP-1 release in body" ^[1]. The case, Cathey v. Ledisa LLC, No. 1:26-cv-06456-EPG, was filed August 13, 2026 in the U.S. District Court for the Eastern District of California ^[1]. Ledisa has not responded in court and has not been found liable; the allegations are unproven ^[1].

The complaint says the patches actually contain berberine, apple cider vinegar, cinnamon, pomegranate, resveratrol and folic acid — plant-based ingredients, not semaglutide, tirzepatide, or any GLP-1 compound ^[1]. The named plaintiff, a Merced, California resident, says she bought a pack from Ledisa's website around March 7, 2026 after reading label claims like "Science Backed Formula" and would not have purchased it had she known what was inside ^[1].

The filing also raises a physical objection that would apply even if a patch did contain the drug. It quotes Sheldon Markowitz, M.D., chief of endocrinology at Episcopal Health Services in New York City, saying transdermal delivery of GLP-1 is "not possible" because the molecules are too large to cross the skin ^[1]. C. Michael White, head of the pharmacy practice department at the University of Connecticut, is quoted saying no GLP-1 medication can currently be absorbed this way, and Nicholas Messinger, M.D., of Mount Sinai Health System says the only FDA-approved formulations are injections and the Wegovy pill — no approved patch exists ^[1]. On the herbal ingredients themselves, physicians quoted in the complaint say there is no evidence they cause weight loss at the doses used, and that those doses are "super off compared to anything that was in the research studies" ^[1].

Ledisa has since relabeled the product as "Berberine Patches," but the complaint alleges the same benefit claims persist and the product is still commonly referred to online as GLP-1 Patches ^[1]. Whether that rebranding changes the legal picture is unresolved; the court has not ruled on it ^[1].

Why it matters for patients

This case is a reminder that products branded around GLP-1 language are not necessarily related to the prescription medications sold as Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or Foundayo. Those drugs are injectable or oral prescription medicines regulated by the FDA. A patch marketed with GLP-1 in its name is a different kind of product, and this complaint alleges it contains none of the hormone or drug class it is named after ^[1].

The lawsuit is framed as false advertising, not a claim that the patches caused harm ^[1]. That distinction matters: someone who bought the product based on the marketing quoted in the complaint may have a purely economic complaint — paying for something that could not do what the label implied — separate from any safety question.

Consumer suits like this one are, according to the source, filling a gap left by slower federal supplement enforcement ^[1]. For shoppers, the practical takeaway from the complaint is that checking the actual ingredient panel, rather than a product's name or badges like "Doctor Approved," is a more reliable way to know what is actually being sold.

What happens next

The case is at an early stage. Ledisa is expected to respond, likely with an answer or a motion to dismiss, and the plaintiff would still need to win class certification for the case to proceed on behalf of a broader group ^[1]. No settlement exists, there is no claim form, and the source that reported this case warns that any messages asking consumers to pay fees or provide banking details for a "Ledisa refund" are scams ^[1]. The timeline for further rulings is not yet known.